Trump Buys SpaceX Shares After Record IPO 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Tesla Raises Cybertruck Prices by $5,000 in US 
Add as a preferred source on Google
DURHAM, N.C., May 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 8:40 a.m. ET at the InterContinental Boston Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
